

Accepted Manuscript

Title: Reduced Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients

Author: Nicolas J. Llosa, Kenneth R. Cooke, Allen Chen, Christopher Gamper, Orly Klein, Elias Zambidis, Brandon Luber, Gary Rosner, Nicholas Siegel, Mary Jo Holuba, Nancy Robey, Masanori Hayashi, Richard J. Jones, Ephraim Fuchs, Matthias Holdhoff, David M. Loeb, Heather J. Symons


PII: S1083-8791(17)30634-1
DOI: <http://dx.doi.org/doi: 10.1016/j.bbmt.2017.08.012>
Reference: YBBMT 54764

To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 14-6-2017
Accepted date: 9-8-2017

Please cite this article as: Nicolas J. Llosa, Kenneth R. Cooke, Allen Chen, Christopher Gamper, Orly Klein, Elias Zambidis, Brandon Luber, Gary Rosner, Nicholas Siegel, Mary Jo Holuba, Nancy Robey, Masanori Hayashi, Richard J. Jones, Ephraim Fuchs, Matthias Holdhoff, David M. Loeb, Heather J. Symons, Reduced Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients, *Biology of Blood and Marrow Transplantation* (2017), <http://dx.doi.org/doi: 10.1016/j.bbmt.2017.08.012>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Reduced Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients

Nicolas J. Llosa*, Kenneth R. Cooke, Allen Chen, Christopher Gamper, Orly Klein, Elias Zambidis, Brandon Luber, Gary Rosner, Nicholas Siegel, Mary Jo Holuba, Nancy Robey, Masanori Hayashi, Richard J. Jones, Ephraim Fuchs, Matthias Holdhoff, David M. Loeb, Heather J. Symons

Blood and Marrow Transplantation Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland

*Corresponding Author, contact information:

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and
The Johns Hopkins University School of Medicine
Bunting-Blaustein Cancer Research Building I (CRB 1)
1650 Orleans St., Room 4M-55
Baltimore, MD 21287
Office: 410-502-8104
Fax: 410-614-0549
Cell: 617-943-4843
Email: nllosa1@jhmi.edu

Short Title: Reduced intensity haploBMT with PT/Cy for pediatric, adolescent, and young adult solid tumors

Key Points

- Reduced intensity haploBMT with post-transplant cyclophosphamide is a safe and feasible treatment for pediatric and young adult patients with high risk solid tumors.

Highlights

- RIC haploBMT with post-transplant cyclophosphamide for high risk solid tumors.
- Platform is a safe and feasible treatment for pediatric and young adult patients.
- Excellent rates of engraftment and low incidences of NRM and acute/chronic GVHD.
- Provides a new, non-tolerant immune system for post-transplant relapse therapies.

ABSTRACT

High risk, recurrent, or refractory solid tumors in pediatric, adolescent and young adult (AYA) patients have an extremely poor prognosis despite current intensive treatment regimens. We piloted an allogeneic bone marrow transplant (alloBMT) platform using a reduced intensity conditioning (RIC) and partially HLA-mismatched (haploidentical) related donors for this

Download English Version:

<https://daneshyari.com/en/article/8430743>

Download Persian Version:

<https://daneshyari.com/article/8430743>

[Daneshyari.com](https://daneshyari.com)